Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure
NCT ID: NCT03727828
Last Updated: 2020-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2018-11-15
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease
NCT05015270
Predicting Heart Failure Outcomes With Biomarkers and Imaging
NCT07332520
Biomarkers for Human Heart Failure
NCT03905252
Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
NCT06690684
Early Assessment of Impaired Cardiac Function in Patients With Diabetes Mellitus
NCT05484817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with heart failure
Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
Patients with heart failure
Participants will have serial blood collection on medical therapy for heart failure
healthy control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients with heart failure
Participants will have serial blood collection on medical therapy for heart failure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Symptomatic (NYHA class II-IV) heart failure (as diagnosed by clinician, radiographic images, or abnormal natriuretic peptide level)
3. Hospital admission, Emergency Department visit, or outpatient diuretic escalation of therapy for destabilized HF at least once in the 6 months prior to enrollment
Exclusion Criteria
2. Cardiac transplantation or revascularization indicated or expected within 6 months
3. Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory volume in 1 sec \<1 L (when diagnosed as standard of care)
4. Subject unable or unwilling to provide written informed consent
5. Coronary revascularization (percutaneous coronary intervention or bypass surgery) within the previous 3 months
6. Progressive neurological disease
7. Pregnancy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Yangpu Hospital
UNKNOWN
Shanghai Municipal Hospital of Traditional Chinese Medicine
OTHER
Huashan Hospital Baoshan Branch
UNKNOWN
Shanghai Zhongye Hospital
UNKNOWN
Shanghai BaoshanLuodianHospital
UNKNOWN
Shanghai Shibei Hospital
UNKNOWN
Nantong Sixth People's Hospital
UNKNOWN
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ya-Wei Xu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dachun Xu, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Tenth People's Hospital, Tongji University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wang Z, Zhu Z, Shen J, Zhang Y, Wang T, Xu Y, Jiang D, Liu W. Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study. Lipids Health Dis. 2024 Sep 12;23(1):294. doi: 10.1186/s12944-024-02282-y.
Ma T, Huang R, Xu Y, Lv Y, Liu Y, Pan X, Dong J, Gao D, Wang Z, Zhang F, Yan C, Ong SB, Su Y, Xu D. Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial. J Transl Med. 2023 Jan 12;21(1):21. doi: 10.1186/s12967-022-03859-w.
Su Y, Sun Y, Tang Y, Li H, Wang X, Pan X, Liu W, Zhang X, Zhang F, Xu Y, Yan C, Ong SB, Xu D. Circulating miR-19b-3p as a Novel Prognostic Biomarker for Acute Heart Failure. J Am Heart Assoc. 2021 Oct 19;10(20):e022304. doi: 10.1161/JAHA.121.022304. Epub 2021 Oct 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRAGON-HF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.